Most Read Articles
07 May 2015
The treatment armamentarium of atopic dermatitis (AD) includes pharmaceuticals like emollients, topical corticosteroids, and topical calcineurin inhibitors. Recently available, medical devices are a newer class of topical, non-steroidal, semi-solid formulation for the treatment of AD and touted to possess emollient, anti-inflammatory, and anti-pruritic properties. To determine the role of medical devices in flare and remission management in AD, a panel of local experts from the field of dermatology, paediatric dermatology, and allergy convened to review the available evidence and highlights of the meeting are reported here.
4 days ago
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.
24 Nov 2017
It appears that patients with psoriasis have lesser health-related quality of life (HRQoL) burden than those with hidradenitis suppurativa (HS), a recent study has found.
12 Nov 2017
Active and passive smoking are associated with atopic dermatitis, a new study from Korea reveals.

MKTP delivers long-term repigmentation in vitiligo, other leukodermas

30 Jul 2017

Melanocyte-keratinocyte transplantation procedure (MKTP) confers satisfactory long-term repigmentation in patients with leukoderma, with repigmentation lasting for at least 72 months, reports a recent study.

Researchers conducted a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014 to assess long-term repigmentation of MKTP in vitiligo and other leukodermas. A 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI) were utilized to evaluate repigmentation.

MKTP was performed at 236 anatomically based lesions (ABLs) in a total of 100 patients, of which 63 with 157 ABLs had available long-term data (12 to 72 months; median 24 months).

VASI scores improved in segmental vitiligo (‒75.6±24.6 percent), nonsegmental vitiligo (‒59.2±36.6 percent) and physical leukoderma (‒32.4±33.5 percent). In vitiligo, 53 percent of ABLs maintained >75 percent repigmentation at 24 months after MKTP, 64 percent at 48 months and 53 percent at 72 months.

Age, skin photoype and anatomic location of ABLs did not show any significant impact on the outcome of treatment.

These results support a previous study, which found MKTP to be effective and well-tolerated based upon categorical and VASI assessments of repigmentation. [J Am Acad Dermatol 2012;66:785-93]

The current study is limited by the retrospective design with uncontrolled, postoperative adjuvant treatments and inconsistent compliance to scheduled follow-up evaluations, according to researchers, adding that persistence of pigmentation after MKTP is a critical consideration for efficacy.

Editor's Recommendations
Most Read Articles
07 May 2015
The treatment armamentarium of atopic dermatitis (AD) includes pharmaceuticals like emollients, topical corticosteroids, and topical calcineurin inhibitors. Recently available, medical devices are a newer class of topical, non-steroidal, semi-solid formulation for the treatment of AD and touted to possess emollient, anti-inflammatory, and anti-pruritic properties. To determine the role of medical devices in flare and remission management in AD, a panel of local experts from the field of dermatology, paediatric dermatology, and allergy convened to review the available evidence and highlights of the meeting are reported here.
4 days ago
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.
24 Nov 2017
It appears that patients with psoriasis have lesser health-related quality of life (HRQoL) burden than those with hidradenitis suppurativa (HS), a recent study has found.
12 Nov 2017
Active and passive smoking are associated with atopic dermatitis, a new study from Korea reveals.